A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer.

CONCLUSION: The combination of enobosarm and pembrolizumab was well tolerated with a modest clinical benefit rate of 25% at 16 weeks in heavily pretreated AR+ TNBC without pre-selected PD-L1. Future clinical trials combining AR targeted therapy with immune checkpoint inhibitor (ICI) for AR+ TNBC warrant investigation.
PMID: 33141975 [PubMed - as supplied by publisher]

Source: The Oncologist - November 3, 2020 Category: Cancer & Oncology Authors: Yuan Y, Lee JS, Yost SE, Frankel PH, Ruel C, Egelston CA, Guo W, Gillece JD, Folkerts M, Reining L, Highlander SK, Robinson K, Padam S, Martinez N, Tang A, Schmolze D, Waisman J, Sedrak M, Lee PP, Mortimer J Tags: Oncologist Source Type: research